1.70% 0.0039

Handel nachbörslich: .23 -0.0039 -1.67%

Calidi Biotherapeutics Inc (CLDI)

Überblick Nachrichten Preisverlauf Forum Prognose

Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten

Millennium Management LLC Increases Stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma, PhD, as CEO to Lead Next Growth Phase - citybuzz -

Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025 - citybuzz -

Calidi Biotherapeutics Presents systemic oncolytic platform - GlobeNewswire

Calidi Biotherapeutics (CLDI) Showcases Innovative CLD-401 Thera - GuruFocus

Revolutionary Cancer Treatment Breakthrough: Calidi's New Systemic Delivery Platform Wows ASCO Conference - Stock Titan

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Globe and Mail

Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World

Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights - marketscreener.com

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire

Calidi Biotherapeutics Secures FDA Green Light for Cancer Trial as New CEO Reveals Q1 Financials - Stock Titan

Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World

Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

CLDICalidi Biotherapeutics Inc Latest Stock News & Market Updates - Stock Titan

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail

Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World

Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX

Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus

Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire

Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan

Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times

Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan

Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa

Zealand names former Lilly exec Singh as CSO - BioCentury

Calidi Biotherapeutics appoints new CEO - Investing.com

Calidi (CLDI) Appoints New CEO as Eric Poma Assumes Leadership | - GuruFocus

Calidi Biotherapeutics Appoints New CEO Eric Poma - TipRanks

Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director - TradingView

Calidi Biotherapeutics Announces Chief Executive Officer - GlobeNewswire

New Calidi Bio CEO Brings $400M Funding Success Record: Strategic Shift for Cancer Treatment Pioneer - Stock Titan

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor - The Globe and Mail

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - The Manila Times

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 - GlobeNewswire

Cancer Breakthrough Alert: Top Oncologist Reveals New FDA-Cleared Stem Cell Therapy Development - Stock Titan

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors - The Manila Times

FDA Green Lights Revolutionary Cancer Treatment: Stem Cells Combined With Virus to Fight Multiple Tumors - Stock Titan

Calidi Biotherapeutics Announces Appointment of Guy Travis - GlobeNewswire

Cancer Drug Developer Calidi Bio Strengthens Leadership: Renowned Oncologist Takes CMO Role - Stock Titan

Calidi Biotherapeutics Appoints New Chief Medical Officer - TipRanks

CLDI stock touches 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa

CLDI stock touches 52-week low at $0.42 amid market challenges - Investing.com India

Press Release Distribution & PR Platform - ACCESS Newswire

ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa

Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan

Ähnlich wie CLDI